Global Healthcare M&A Report – April 2026: 61 Deals Worth $36.17 Billion

According to incomplete statistics from Arterial Intelligence, in April 2026, there were a total of 61 mergers and acquisitions in the global healthcare sector, with the publicly disclosed total transaction amount being approximately $36.173 billion (about 248.779 billion RMB). In the Chinese market, there were 8 M&A events, with a disclosed total transaction amount of approximately $27.5089 million; in overseas markets, there were 53 M&A events, with a disclosed total transaction amount of approximately $36.145 billion.

TPG and Blackstone Group Acquire Hologic, a Developer of Medical Imaging Systems and Diagnostic Products, for $18.3 Billion in the Largest M&A Deal of the Month.

Gilead Sciences Completes Acquisition of Arcellx; Anito-cel Expected to Be Commercially Available Soon

On April 28, 2026, Gilead successfully completed the acquisition of Arcellx. According to the terms of the deal, Gilead acquired Arcellx for $115 per share in cash, plus a non-transferable contingent value right (CVR) of $5 per share, with an implied total equity value at closing of approximately $7.8 billion. Following the completion of the merger, Arcellx has become a wholly owned subsidiary of Gilead, and Arcellx’s common stock will be delisted from the NASDAQ Global Select Market. This acquisition builds on the successful collaboration between Kite (a Gilead company) and Arcellx, granting Gilead full control over anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR T-cell therapy for multiple myeloma. Through the integration of...anito-celBy acquiring full ownership and eliminating future profit-sharing, milestone payments, and royalty obligations, Gilead is poised to accelerate the development process, streamline decision-making, and maximize the project's long-term potential.

Gene Therapy Developer BioMarin Completes Acquisition of Amicus Therapeutics

On April 27, 2026, gene therapy developer BioMarin completed the acquisition of Amicus Therapeutics in an all-cash transaction at $14.50 per share, with a total equity value of approximately $4.8 billion. This acquisition will strengthen BioMarin's commercial portfolio by adding two drug combinations for lysosomal storage disorders: Galafold (migalastat), the first oral treatment for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), a two-component therapy for Pompe disease. BioMarin now holds the U.S. rights to DMX-200, a potential first-in-class experimental small molecule drug.InPhase IIIDevelopmentPhase,Used to treat focal segmental glomerulosclerosis (FSGS), a rare and fatal kidney disease.

Major Acquisition Completed: $950 Million Cash Secures Rare Pulmonary Hypertension Asset

On April 21, 2026, British multinational pharmaceutical company GSK announced on April 15, 2026, that it had completed the acquisition of Canadian clinical-stage biopharmaceutical company 35Pharma Inc. for $950 million in cash, acquiring 100% of its equity and all R&D assets. This acquisition will strengthen GSK's pipeline in respiratory, immunology and inflammation (RI&I), and cardiometabolic diseases, addressing gaps in its portfolio for pulmonary arterial hypertension treatments.

RMB 11.0476 Million: A Chongqing IVD Company Sold

On April 25, 2026, BGI Genomics Co., Ltd. announced that the company had acquired 100% equity of Chongqing Xinyi Life Technology Co., Ltd. for 11.0476 million yuan of its own funds. This transaction constitutes a related party transaction but does not constitute a major asset restructuring. BGI stated that this acquisition is conducive to enhancing the company’s overall competitiveness, fostering new growth points in performance, and aligns with the company's long-term strategy and the interests of all shareholders.

Diagnostic Product Developer and Manufacturer QuidelOrtho Completes Acquisition of LEX Diagnostics

Large IVD Foreign Enterprise Officially Changes Ownership

On April 7, 2026, Hologic, a developer of medical imaging systems as well as diagnostic and surgical products, announced that private equity firms Blackstone Group and TPG completed their acquisition of the company. The deal, initially disclosed in October 2025, values Hologic at up to $18.3 billion and will take it private. Under the terms of the transaction, Hologic shareholders will receive $76 per share in cash, along with a non-tradable contingent value right (CVR) — this entitles shareholders to receive up to an additional $1.50 per share in two separate payments, with a combined maximum payout of $3 per share, bringing the total cash consideration to $79 per share. Hologic’s shares will cease trading and be delisted from the Nasdaq.

Electronic Medical Records and Clinic Management Platform Aesthetic Record Acquires JOYA Health to Create the First Ecosystem Connecting Employee Benefits with a National Network of Skin Health in China

On April 28, 2026, Aesthetic Record, an electronic medical record and clinic management platform, acquired JOYA Health, a corporate skin health and wellness benefits provider that connects employers/employees with certified dermatology and aesthetic care services. This agreement reflects a broader shift toward specialized, consumer-driven health benefits. As skin health plays an increasingly important role in employer health strategies, the merged company is expected to expand provider accessibility, improve treatment outcomes, and increase provider traffic through a more integrated model.

Healthcare Support Coordination Platform One Call Completes Acquisition of Data Dimensions, Building Infrastructure for the Healthcare Ecosystem

On April 15, 2026, One Call, a medical auxiliary care coordination platform, completed the acquisition of Data Dimensions. Following the completion of the transaction, the organizations will begin operating as a unified platform—integrating care coordination, clinical workflows, data exchange, and payment into a continuously interconnected system.

Healthcare IT and Business Solutions Provider DAS Health Acquires Two Divisions of Prime Holdings, Expanding Nationwide Operations

On April 9, 2026, DAS Health, a healthcare IT and business solutions provider, announced the acquisition of Prime Care Technologies and the Prime Cloud division under Prime Holdings. This transaction expands DAS Health's business coverage and further solidifies its position as the most comprehensive provider of managed IT, cybersecurity, and professional services specifically built for the healthcare industry.

Shaanxi Ruisheng Biotechnology Co., Ltd. Completes Acquisition of 51% Equity in Changzhou Tianning Longyang Jinboli Dental Clinic

On April 3, 2026, Shanghai Haily Biotechnology Co., Ltd. announced today the progress of its controlling subsidiary, Shaanxi Ruisheng Biotechnology Co., Ltd., in acquiring the equity of seven dental chain companies. According to the company's previous board resolution, Ruisheng Biotech plans to acquire 51% of the equity in seven dental chain companies located in Yangzhou and Changzhou for a total of RMB 61.2 million in its own funds. Currently, the industrial and commercial change registration procedures for the equity transfer of one of the target companies, Changzhou Tianning Longyang Jinboli Dental Clinic Co., Ltd., were completed on April 1, 2026. Ruisheng Biotech officially holds 51% of the equity, with Zou Chunyang and Xie Shouliang holding the remaining 44% and 5% equity respectively. This acquisition is an important measure by Haily Biotech to expand its business in the field of dental medical services through its subsidiary Ruisheng Biotech.

Rehabilitation Medical Institution ROC Expands Patient Services Through Acquisition of ActiveEDGE

On April 1, 2026, Regenerative Orthepedic Center, a rehabilitation medical institution, acquired ActiveEDGE Physical Therapy & Wellness Center, an established physical therapy provider serving customers in the Portland area. This acquisition expands ROC's ability to deliver fully coordinated care by directly integrating physical therapy services into its care model.

Long-Term Care Facility Company Extendicare Acquires CBI Home Health

On April 1, 2026, Extendicare Inc., a long-term care facilities company, announced that its wholly-owned home healthcare subsidiary, ParaMed Inc., completed the previously announced acquisition of the equity interests in CBI Home Health and CBI (GP) 3 Inc. and their respective subsidiaries (collectively referred to as "CBI Home Health"). The acquisition was completed at a cash purchase price of $570 million, subject to customary adjustments, with an additional estimated lease liability of approximately $13.6 million under IFRS 16 - Leases.

Vertically Integrated Medical and Wellness Cannabis Operator Curaleaf Completes Acquisition of Remaining Shares of Four 20 Pharma

On April 30, 2026, Curaleaf, a vertically integrated medical and wellness cannabis operator, completed the acquisition of the remaining 45% stake in Four 20 Pharma GmbH. The full acquisition of Four 20 Pharma strengthens Curaleaf's vertically integrated global supply chain, from its own cultivation sources in Portugal and Canada to licensed distribution in Germany, ensuring true seed-to-patient quality assurance and comprehensive regulation at every stage.

Dawn Medical Technologies Acquires Controlling Stake in Vietnam's Pinnacle Health

On April 23, 2026, Dawn Medical Technologies, a medical technology company, announced the acquisition of a controlling stake in Pinnacle Health Equipment Joint Stock Company, one of Vietnam's largest and most established full-spectrum medical technology distributors. This strategic transaction marks Dawn's entry into the fast-growing Vietnamese market and represents CBC Group's first acquisition in the Southeast Asian medical technology sector.

Next-Gen AI-Native Brokerage Platform Gyde Acquires Avid Health, Launching AI-Supported Brokerage Platform in the Health Insurance Market

On April 2, 2026, Gyde, the next-generation AI-native brokerage platform, announced the acquisition of Avid Health, a top Medicare agency in Palm Beach, Florida. The acquisition highlights Gyde's ambition to collaborate with and acquire leading insurance agencies, equipping them with an AI-native platform that automates complex administrative processes, empowering brokers to offer more proactive guidance in the fields of insurance, wealth, and health decision-making.

In each of the above fields, only up to 3 M&A events are displayed.Welcome ImmediatelyScan the QR code to add the assistantObtainCompleteMonthly ReportAndApply for a Free Trial Database, if added, please inquire proactively: